Laurus Labs Reports Sharp Profit Jump and Plans Two Major Acquisitions

Laurus Labs reported a more than twofold increase in consolidated net profit to ₹436.74 crore for the September quarter. Revenue from operations rose to ₹2,206.37 crore from ₹1,653.47 crore in the same period last year. This growth was supported by contributions from the contract development and manufacturing organisation business, specifically small molecules, and the Affordable Medicine division. The company also declared an interim dividend of ₹1 per equity share of ₹2 face value.

Acquisitions And Strategy

Laurus is acquiring a 60% stake in Galenvs Sciences Inc., a contract research and development organisation based in Montreal, Canada, at a pre-money valuation of $3.50 million. The company plans to invest $3.75 million through a primary infusion of $2.75 million and a secondary acquisition of $1 million. Galenvs focuses on custom oligonucleotide synthesis and functional magnetic-nanoparticle technologies for diagnostics and therapeutics markets. Meanwhile, the board approved acquiring a 52% stake in Hyderabad-based SI & C Resins at a pre-money valuation of ₹30 crore. Laurus will invest a total of ₹32.50 crore in the firm, which makes polymer and silica-based products for the chemical, pharmaceutical, and biotechnology industries.

Leadership Statement

Founder and CEO Satyanarayana Chava stated that the quarterly performance shows the strength of the company's platform and affordable medicines portfolio. Laurus is carrying out a transformation strategy and has started its first commercial-scale peptide plant in Visakhapatnam to meet growing demand for peptide therapeutics. The firm has also invested in oligonucleotides and peptide-resins technologies.

Context

Pharmaceutical companies often use acquisitions and new production facilities to expand their product portfolios and enter specialized global markets like advanced therapeutics. Investments in contract research and manufacturing help firms diversify revenue streams beyond traditional drug sales. Such operational shifts reflect wider efforts within the healthcare sector to build capacity for complex biological molecules and custom research.